SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is currently experiencing significant market attention driven by high-profile institutional accumulation, including major positions from Millennium Management and Janus Henderson, despite recent volatility stemming from a bizarre executive controversy. Investors remain focused on the potential of NXC-201 as a disruptive one-and-done BCMA CAR-T therapy, with the community actively debating the company's BLA timeline, upcoming clinical data, and the possibility of a strategic buyout.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

The Shiba Inu community remains highly polarized as supporters highlight the token's evolving ecosystem and burning mechanisms, while detractors dismiss it as an aging project in a potential death spiral. Investors are actively debating the viability of long-term holding versus the risks of holding meme-centric assets in the current market.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is seeing intense volatility as investors weigh a significant revenue decline against strategic shifts toward higher-margin AI infrastructure integration. The community remains sharply divided, with bulls pointing to the company's critical role in Dell's AI rack assembly and potential for growth, while skeptics emphasize the lack of customer diversification and heavy reliance on a single partner.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide ADR (WRD) is trending following multiple aggressive share buyback announcements and strategic partnerships with companies like Lenovo and Chery, though investor sentiment remains divided over the company's path to profitability and execution pace. The community is actively debating whether these aggressive buybacks are a bullish signal of undervaluation or a defensive measure, while focusing on upcoming Q1 earnings and 13F filings for signs of institutional momentum.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is facing significant price volatility driven by community concerns regarding the departure of a major subnet developer and broader debates about the project's level of decentralization. Despite these headwinds, many investors view the current dip as a strategic accumulation opportunity, maintaining long-term conviction in the network's AI infrastructure potential and staking yields.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is drawing significant community interest as investors increasingly prioritize monthly cash flow strategies that pair Nasdaq-100 exposure with high-yield income potential. Conversations are currently centered on the fund's competitive distribution consistency, its total return profile compared to other derivative-income peers, and its role as a core holding for long-term passive income builders.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is experiencing intense community focus as traders debate the impact of ongoing airdrop distributions and the technical implications of the recent Wanchain bridge exploit. The community remains deeply divided, balancing high-conviction bullish sentiment regarding the protocol's privacy-focused utility against concerns about potential sell pressure from large wallet movements and historical price volatility.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is gaining traction as investors anticipate its expansion to the Ethereum mainnet and a token merger, which many view as key drivers for long-term growth and institutional adoption. The community remains focused on the platform's dominance within the Base ecosystem and its potential as a core liquidity infrastructure play.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

ProShares Ultra Bloomberg Crude Oil is seeing heightened attention as traders react to conflicting reports regarding a potential US-Iran ceasefire and the status of the Strait of Hormuz. While some investors are betting on a supply relief rally, others remain skeptical about the durability of these diplomatic headlines, leading to intense volatility and fierce debate regarding the long-term impact on global energy pricing.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate whether the asset is forming a significant macro bottom following its recent consolidation, with many monitoring critical support levels and potential short-squeeze signals. The community is actively discussing ongoing institutional adoption and the impact of the latest network transaction milestones on long-term price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why You Should Add LXRX Stock to Your Portfolio Now

Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Key PointsLexicon Pharmaceuticals focuses on precision medicines for chronic conditions, bolstered by significant revenue growth from its core drug programs...

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon (LXRX) delivered earnings and revenue surprises of +100.00% and +141.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200-Day Moving Average   - Here's What Happened

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200-Day Moving Average - Here's What Happened...

Lexicon Pharmaceuticals (LXRX) to Release Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-lexicon-pharmaceuticals-inc-stock...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 1-Year High  - Here's Why

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High - What's Next...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High  - Should You Buy?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High - Still a Buy...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 6.3% Higher - Still a Buy?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Up 6.3% - Here's What Happened...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average - What's Next?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Pass Above 200 Day Moving Average - Here's What Happened...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.7% Higher - Time to Buy?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.7% Higher - Should You Buy...

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Lexicon Pharmaceuticals Inc

Novo Nordisk Advances Obesity Pipeline With Early-Stage Oral Drug Trial From Lexicon Deal

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

LXRXLexicon Pharmaceuticals Inc

Fundamentals

Latest LXRX News